COVID‑19 Rates Climbing in 48 States – What Rhode Islanders Should Know About the New 2026‑27 Vaccine

Late August saw a puzzling mix of numbers: wastewater data flagged “very high” COVID‑19 activity in Texas, “high” in Mississippi, while most of the country sat at “low” or “very low” levels. The CDC’s latest briefing said 48 states are seeing a rise in cases, a reminder that the virus still likes to surprise us.

In Rhode Island, the picture looks calmer. Local wastewater testing shows only a “very low” viral load, and hospitals haven’t been flooded with patients. Still, the federal government isn’t sitting still. The Food and Drug Administration just gave the green light to the 2026‑27 COVID‑19 vaccine, but—and this is a big but—it’s now aimed solely at the XFG strain, the variant that was dominant when the formula was chosen back in May.

What does that mean for the everyday RI resident? The first shipments are slated to roll into pharmacies, doctors’ offices, and community clinics later this month. You’ll likely see the new vials on the shelf, but they won’t be handed out to everyone right away. The FDA’s guidance mirrors the flu‑shot process: prioritize those at highest risk.

Who’s first in line? Anyone 65 years or older, plus younger folks who have at least one condition that can make COVID‑19 more severe—think asthma, diabetes, obesity, heart or lung disease, and even pregnancy. The brand‑specific age caps differ a bit: Moderna’s Spikevax is cleared for high‑risk patients as young as six months, Pfizer‑BioNTech for those five and up, while Moderna’s newer mNexspike and Novavax are limited to 12‑year‑olds and older.

Even with the uptick in case counts, emergency rooms across the nation are reporting fewer COVID‑related visits than during the height of the pandemic. Experts say that’s the result of community immunity—most infections are now mild. Still, they urge parents to keep sick kids at home and to stay current on any recommended shots.

Back‑to‑school hiccups are already popping up elsewhere. A Texas school closed its doors for two days after a “rapid spread” event, and a Louisiana academy shut down for a day “out of an abundance of caution.” Those stories echo the seasonal rhythm Dr. William Schaffner of Vanderbilt noted on NBC’s “Today” — a mid‑summer wave followed by a winter surge.

Now, about the bill: will insurance foot the cost? Medicare Part B will cover the FDA‑approved vaccine with no copay when you get it from a participating provider. Many private insurers, through the AHIP coalition, have said they’ll cover the full price as well. The hitch? The CDC’s advisory committee on vaccines hasn’t issued a formal recommendation for the 2026‑27 season yet, thanks to a legal stalemate. That gap could cause some insurers to pause before confirming coverage, so a quick call to your carrier never hurts.

Bottom line? The new XFG‑focused vaccine is on its way, but you’ll need to check eligibility, talk to your pharmacist or doctor, and confirm your insurance details before you schedule an appointment.